uniQure N.V. (NASDAQ:QURE) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of uniQure N.V. (NASDAQ:QURE) have been assigned a consensus rating of “Moderate Buy” from the seventeen research firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, six have given a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $42.8333.

QURE has been the topic of a number of analyst reports. Barclays lowered their price target on uniQure from $31.00 to $25.00 and set an “equal weight” rating on the stock in a research report on Monday, March 23rd. Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $9.00 price target (down from $55.00) on shares of uniQure in a research report on Monday, March 2nd. HC Wainwright lowered their price target on uniQure from $70.00 to $50.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Finally, Stifel Nicolaus set a $28.00 price target on uniQure in a research report on Tuesday, May 5th.

uniQure Stock Performance

Shares of NASDAQ:QURE opened at $28.53 on Friday. The business’s fifty day moving average price is $20.18 and its two-hundred day moving average price is $21.92. uniQure has a fifty-two week low of $8.73 and a fifty-two week high of $71.50. The stock has a market capitalization of $1.80 billion, a price-to-earnings ratio of -8.20 and a beta of 0.87. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The firm had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. As a group, analysts predict that uniQure will post -3.68 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Jeannette Potts sold 3,412 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $30,912.72. Following the sale, the insider owned 138,483 shares in the company, valued at approximately $1,254,655.98. This represents a 2.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Matthew C. Kapusta sold 14,581 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $132,103.86. Following the sale, the chief executive officer owned 660,658 shares in the company, valued at $5,985,561.48. The trade was a 2.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 75,801 shares of company stock worth $1,406,757 over the last ninety days. Company insiders own 4.79% of the company’s stock.

Institutional Trading of uniQure

Several large investors have recently made changes to their positions in QURE. Torren Management LLC bought a new stake in shares of uniQure during the fourth quarter worth $28,000. Jones Financial Companies Lllp grew its holdings in shares of uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares during the last quarter. IFP Advisors Inc bought a new stake in shares of uniQure during the fourth quarter worth $48,000. Smartleaf Asset Management LLC bought a new stake in shares of uniQure during the fourth quarter worth $48,000. Finally, CIBC Private Wealth Group LLC bought a new stake in shares of uniQure during the third quarter worth $50,000. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.